Table 1

Baseline characteristics of the total study population and according to the randomised groups

Total population (n=117)Placebo (n=59)Tocilizumab (n=58)P value
Age, years, mean (SD)60 (8.9)60.1 (9.9)59.8 (7.7)0.859
Female, n (%)14 (12.0)5 (8.5)9 (15.5)0.241
Body mass index, kg/m2, mean (SD)28.1 (4.0)27.4 (4.4)28.8 (3.3)0.055
Hypertension, n (%)43 (36.8)17 (28.8)26 (44.8)0.072
Diabetes mellitus, n (%)21 (17.9)10 (16.9)11 (19)0.776
Current smoking, n (%)32 (27.6)17 (28.8)15 (26.3)0.763
Previous myocardial infarction, n (%)16 (13.7)7 (11.9)9 (15.5)0.565
Symptom onset to inclusion, days, median (25, 75 percentiles)2 (1, 3)2 (1, 3)2 (2, 3.5)0.197
Maximum TnT, ng/L, median (25, 75 percentiles)271 (134, 935)271 (143, 800)315 (134, 1064)0.867
PCI, n (%)88 (75.2)47 (79.7)41 (70.7)0.261
Aspirin, n (%)116 (99.1)59 (100)57 (98.3)0.496
Clopidogrel, n (%)64 (54.7)32 (54.2)32 (55.2)0.919
Ticagrelor, n (%)53 (45.3)27 (45.8)26 (44.8)0.919
Low molecular weight heparin, n (%)105 (90.5)54 (91.5)51 (89.5)0.706
Statin, n (%)106 (90.6)53 (89.8)53 (91.4)0.774
Betablocker, n (%)90 (76.9)45 (76.3)45 (77.6)0.866
Neutrophil count, 109/L, median (25, 75 percentiles)4.8 (3.4, 6.1)4.5 (3.4, 6.0)5.1 (3.4, 6.4)0.471
  • Numbers are given as mean (SD), median (25, 75 percentiles) or numbers (%), as appropriate.

  • P value refers to difference between the placebo and tocilizumab groups.

  • PCI, percutaneous coronary intervention; TnT, troponin T.